Compare Stocks: BIAF, MGRX, GXAI, and BMGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIAF bioAffinity Technologies	$6.19 +2.3%	$7.74	$4.56 ▼ $80.70	$3.64M	-1.25	2.73 million shs	105,375 shs
BMGL Basel Medical Group	$3.17 -3.4%	$4.82	$2.95 ▼ $21.72	$5.19M	0.53	1.65 million shs	13,376 shs
GXAI Gaxos.ai	$0.49 -5.6%	$0.75	$0.47 ▼ $2.63	$5.54M	1.08	227,679 shs	246,072 shs
MGRX Mangoceuticals	$0.42 -4.4%	$0.45	$0.16 ▼ $2.75	$9.43M	1.98	609,979 shs	575,604 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIAF bioAffinity Technologies	+2.31%	-16.46%	-59.46%	-50.28%	-84.19%
BMGL Basel Medical Group	-3.35%	-8.65%	-33.47%	-47.08%	-83.59%
GXAI Gaxos.ai	-5.60%	-11.52%	-35.50%	-56.13%	-71.35%
MGRX Mangoceuticals	-4.37%	+8.63%	+1.70%	+12.12%	-81.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIAF bioAffinity Technologies	$6.19 +2.3%	$7.74	$4.56 ▼ $80.70	$3.64M	-1.25	2.73 million shs	105,375 shs
BMGL Basel Medical Group	$3.17 -3.4%	$4.82	$2.95 ▼ $21.72	$5.19M	0.53	1.65 million shs	13,376 shs
GXAI Gaxos.ai	$0.49 -5.6%	$0.75	$0.47 ▼ $2.63	$5.54M	1.08	227,679 shs	246,072 shs
MGRX Mangoceuticals	$0.42 -4.4%	$0.45	$0.16 ▼ $2.75	$9.43M	1.98	609,979 shs	575,604 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIAF bioAffinity Technologies	+2.31%	-16.46%	-59.46%	-50.28%	-84.19%
BMGL Basel Medical Group	-3.35%	-8.65%	-33.47%	-47.08%	-83.59%
GXAI Gaxos.ai	-5.60%	-11.52%	-35.50%	-56.13%	-71.35%
MGRX Mangoceuticals	-4.37%	+8.63%	+1.70%	+12.12%	-81.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIAF bioAffinity Technologies	1.00	Sell	N/A	N/A
BMGL Basel Medical Group	1.00	Sell	N/A	N/A
GXAI Gaxos.ai	1.00	Sell	N/A	N/A
MGRX Mangoceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BIAF, MGRX, GXAI, and BMGL Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/25/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	MGRX Mangoceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/14/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	BIAF bioAffinity Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIAF bioAffinity Technologies	$5.85M	0.64	N/A	N/A	$24.25 per share	0.26
BMGL Basel Medical Group	$8.90M	0.56	N/A	N/A	$2.44 per share	1.30
GXAI Gaxos.ai	$6.01M	0.87	N/A	N/A	$1.79 per share	0.27
MGRX Mangoceuticals	$460K	19.60	N/A	N/A	$0.93 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIAF bioAffinity Technologies	-$14.91M	-$109.45	N/A	N/A	N/A	-257.30%	-220.52%	-136.76%	11/18/2026 (Estimated)
BMGL Basel Medical Group	-$9.50M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GXAI Gaxos.ai	-$3.90M	-$0.50	N/A	N/A	N/A	-64.81%	-38.79%	-36.99%	11/12/2026 (Estimated)
MGRX Mangoceuticals	-$20.64M	-$1.01	N/A	N/A	N/A	-4,794.60%	-96.39%	-89.60%	N/A

Latest BIAF, MGRX, GXAI, and BMGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGRX Mangoceuticals	N/A	-$0.09	N/A	-$0.09	N/A	$0.08 million
8/12/2026	Q2 2026	GXAI Gaxos.ai	-$0.15	$0.02	+$0.17	$0.02	$1.80 million	$2.46 million
8/7/2026	Q2 2026	BIAF bioAffinity Technologies	-$31.50	-$0.64	+$30.86	-$9.60	$1.70 million	$1.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIAF bioAffinity Technologies	N/A	N/A	N/A	N/A	N/A
BMGL Basel Medical Group	N/A	N/A	N/A	N/A	N/A
GXAI Gaxos.ai	N/A	N/A	N/A	N/A	N/A
MGRX Mangoceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIAF bioAffinity Technologies	0.14	1.44	1.41
BMGL Basel Medical Group	N/A	N/A	N/A
GXAI Gaxos.ai	N/A	10.56	10.56
MGRX Mangoceuticals	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIAF bioAffinity Technologies	1.64%
BMGL Basel Medical Group	N/A
GXAI Gaxos.ai	42.62%
MGRX Mangoceuticals	56.72%

Insider Ownership

Company	Insider Ownership
BIAF bioAffinity Technologies	2.68%
BMGL Basel Medical Group	N/A
GXAI Gaxos.ai	3.17%
MGRX Mangoceuticals	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIAF bioAffinity Technologies	57	601,000	585,000	Not Optionable
BMGL Basel Medical Group	70	1.58 million	N/A	N/A
GXAI Gaxos.ai	3	10.75 million	10.40 million	N/A
MGRX Mangoceuticals	3	21.57 million	18.12 million	Not Optionable

BIAF, MGRX, GXAI, and BMGL Headlines

Recent News About These Companies

Mangoceuticals Secures $2.5 Mln Investment To Advance Antiviral IP Commercialization

October 2, 2026 | rttnews.com

Mangoceuticals, Inc.: Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

October 2, 2026 | finanznachrichten.de

Mangoceuticals Secures Strategic Investment in MangoRx IP Subsidiary

October 1, 2026 | tipranks.com

Mangoceuticals Announces $2.5 Million Subsidiary-Level Investment in MangoRx IP Holdings to Advance Antiviral Portfolio Commercialization

October 1, 2026 | quiverquant.comQ

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

October 1, 2026 | globenewswire.com

Mangoceuticals Terminates Planned Business Combination with Nuclea

August 21, 2026 | tipranks.com

MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 17, 2026 | businesswire.com

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

August 13, 2026 | markets.businessinsider.com

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

August 13, 2026 | globenewswire.com

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

August 13, 2026 | newsfilecorp.comN

Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

August 6, 2026 | markets.businessinsider.com

Mangoceuticals (MGRX) stock jumps over 49% after hours: Here's why

August 6, 2026 | msn.com

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

August 6, 2026 | globenewswire.com

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

August 6, 2026 | newsfilecorp.comN

Mangoceuticals, Inc.: Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

August 5, 2026 | finanznachrichten.de

Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

August 5, 2026 | finance.yahoo.com

Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development

August 5, 2026 | newsfilecorp.comN

Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

August 5, 2026 | globenewswire.com

Mangoceuticals Wins Nasdaq Extension Amid Nuclea Deal Progress

August 4, 2026 | tipranks.com

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF, MGRX, GXAI, and BMGL Company Descriptions

bioAffinity Technologies NASDAQ:BIAF

$6.19 +0.14 (+2.31%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$6.20 +0.01 (+0.21%)

As of 06:04 AM Eastern

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Basel Medical Group NASDAQ:BMGL

$3.17 -0.11 (-3.35%)

Closing price 10/5/2026 03:52 PM Eastern

Extended Trading

$3.23 +0.06 (+1.89%)

As of 04:50 AM Eastern

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Gaxos.ai NASDAQ:GXAI

$0.49 -0.03 (-5.60%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$0.50 +0.01 (+2.46%)

As of 05:35 AM Eastern

Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.

Mangoceuticals NASDAQ:MGRX

$0.42 -0.02 (-4.37%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$0.41 0.00 (-0.96%)

As of 05:48 AM Eastern

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIAF, MGRX, GXAI, and BMGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIAF, MGRX, GXAI, and BMGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIAF, MGRX, GXAI, and BMGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF, MGRX, GXAI, and BMGL Company Descriptions

bioAffinity Technologies NASDAQ:BIAF

Basel Medical Group NASDAQ:BMGL

Gaxos.ai NASDAQ:GXAI

Mangoceuticals NASDAQ:MGRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIAF, MGRX, GXAI, and BMGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIAF, MGRX, GXAI, and BMGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIAF, MGRX, GXAI, and BMGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF, MGRX, GXAI, and BMGL Company Descriptions

bioAffinity Technologies NASDAQ:BIAF

Basel Medical Group NASDAQ:BMGL

Gaxos.ai NASDAQ:GXAI

Mangoceuticals NASDAQ:MGRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools